These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 2516611)
21. Patient characteristics rather than the type of dialyser predict the variability of endothelial derived surface molecules in chronic haemodialysis patients. Grooteman MP; Gritters M; Wauters IM; Schalkwijk CG; Stam F; Twisk J; Ter Wee PM; Nubé MJ Nephrol Dial Transplant; 2005 Dec; 20(12):2751-8. PubMed ID: 16188898 [TBL] [Abstract][Full Text] [Related]
22. Association between phosphate removal and markers of bone turnover in haemodialysis patients. Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746 [TBL] [Abstract][Full Text] [Related]
23. Cardiac troponin I in patients with chronic kidney disease treated conservatively or undergoing long-term haemodialysis. Flisiński M; Strózecki P; Stefańska A; Zarzycka-Lindner G; Brymora A; Manitius J Kardiol Pol; 2007 Sep; 65(9):1068-75; discussion 1076-8. PubMed ID: 17975754 [TBL] [Abstract][Full Text] [Related]
24. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. Redón J; Cea-Calvo L; Lozano JV; Fernández-Pérez C; Navarro J; Bonet A; González-Esteban J; J Hypertens; 2006 Apr; 24(4):663-9. PubMed ID: 16531794 [TBL] [Abstract][Full Text] [Related]
25. [Characteristics of hyperhomocysteinemia in dialysis patients]. Lovcić V; Kes P; Reiner Z Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568 [TBL] [Abstract][Full Text] [Related]
26. Determination of serum oxalate using peroxyoxalate chemiluminescence of free oxalic acid. Albrecht S; Hornak H; Freidt T; Böhm WD; Weis K; Reinschke A J Biolumin Chemilumin; 1993; 8(1):21-4. PubMed ID: 8475780 [TBL] [Abstract][Full Text] [Related]
27. Elevated homocysteine levels in patients with end-stage renal disease. Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160 [TBL] [Abstract][Full Text] [Related]
28. Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1. Yamauchi T; Quillard M; Takahashi S; Nguyen-Khoa M Nephrol Dial Transplant; 2001 Dec; 16(12):2407-11. PubMed ID: 11733634 [TBL] [Abstract][Full Text] [Related]
29. Renal excretion of oxalate in patients with chronic renal failure or nephrolithiasis. Chen SM; Chen TW; Lee YH; Chu WY; Young TK J Formos Med Assoc; 1990 Aug; 89(8):651-6. PubMed ID: 1981225 [TBL] [Abstract][Full Text] [Related]
30. Effects of ascorbic acid and pyridoxine supplementation on oxalate metabolism in peritoneal dialysis patients. Shah GM; Ross EA; Sabo A; Pichon M; Reynolds RD; Bhagavan H Am J Kidney Dis; 1992 Jul; 20(1):42-9. PubMed ID: 1621677 [TBL] [Abstract][Full Text] [Related]
31. The determination of oxalate in haemodialysate and plasma: a means to detect and study 'hyperoxaluria' in haemodialysed patients. Wolthers BG; Meijer S; Tepper T; Hayer M; Elzinga H Clin Sci (Lond); 1986 Jul; 71(1):41-7. PubMed ID: 3709074 [TBL] [Abstract][Full Text] [Related]
32. Plasma oxalate and creatinine and oxalate/creatinine clearance ratios in normal subjects and in primary hyperoxaluria. Evidence for renal hyperoxaluria. Kasidas GP; Nemat S; Rose GA Clin Chim Acta; 1990 Oct; 191(1-2):67-77. PubMed ID: 2073734 [TBL] [Abstract][Full Text] [Related]
33. The effect of vitamin C intake on plasma oxalate in patients on regular haemodialysis. Rolton HA; McConnell KM; Modi KS; Macdougall AI Nephrol Dial Transplant; 1991; 6(6):440-3. PubMed ID: 1876286 [TBL] [Abstract][Full Text] [Related]
35. Plasma level and renal clearance of oxalate in normal subjects and in patients with primary hyperoxaluria or chronic renal failure or both. Constable AR; Joekes AM; Kasidas GP; O'Regan P; Rose GA Clin Sci (Lond); 1979 Apr; 56(4):299-304. PubMed ID: 477214 [TBL] [Abstract][Full Text] [Related]
36. Plasma oxalate in patients with chronic renal failure receiving continuous ambulatory peritoneal dialysis or hemodialysis. McConnell KN; Rolton HA; Modi KS; Macdougall AI Am J Kidney Dis; 1991 Oct; 18(4):441-5. PubMed ID: 1928062 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic studies of oxalate in man. Hautmann R; Osswald H Invest Urol; 1979 Mar; 16(5):395-8. PubMed ID: 429137 [TBL] [Abstract][Full Text] [Related]
38. Correction of subclinical ascorbate deficiency in patients receiving dialysis: effects on plasma oxalate, serum cholesterol, and capillary fragility. Tomson CR; Channon SM; Parkinson IS; McArdle P; Qureshi M; Ward MK; Laker MF Clin Chim Acta; 1989 Apr; 180(3):255-64. PubMed ID: 2743578 [TBL] [Abstract][Full Text] [Related]
39. Plasma profiles and dialysis kinetics of oxalate in patients receiving hemodialysis. Marangella M; Petrarulo M; Mandolfo S; Vitale C; Cosseddu D; Linari F Nephron; 1992; 60(1):74-80. PubMed ID: 1738418 [TBL] [Abstract][Full Text] [Related]
40. Measurement of plasma oxalate in healthy subjects and in patients with chronic renal failure using immobilised oxalate oxidase. Kasidas GP; Rose GA Clin Chim Acta; 1986 Jan; 154(1):49-58. PubMed ID: 3943224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]